Allium Medical Appoints Limor Domnitz Gishri as CEO - New CEO Poised to lead Allium to new cycle of growth



Caesarea, Israel -Nov. 6, 2008 - Allium Medical Group, developer and manufacturer of anatomically and functionally compatible, dynamic, large-caliber, removable stents, announced today the appointment of  CFO and Vice President of Business Development, Sales & Marketing, Limor Domnitz Gishri, CPA, Adv. to CEO. Ms. Domintz Gishri brings to the position extensive experience in the financial, legal and business development aspects of the medical device industry.   In this new role, Domintz Gishri will be responsible for leading the company's strategic growth while addressing changing market conditions.


Founded in 2001, Allium develops site-specific stents for various uses with applications in the urinary and gastro-intestinal tract. Allium completed CE Marking for its biliary and ureteral stents, and commenced distribution of its biliary stents as of June 2007 and its ureteral stents as of December 2007 in various European markets including Italy, United Kingdom, Germany, Benelux, Spain, Scandinavia and South Africa. Follow-on orders have been received and delivered.

Prior to joining Allium, Domnitz Gishri was at the law firm of Shiboleth, Yisraeli, Roberts, Zisman & Co., in the hi-tech department. Before that she was an auditor of public and private hi-tech and bio-tech companies at Kost Forer Gabbay & Kasierer (the Israeli representative of Ernst & Young). In addition, she is a lecturer of various business and accounting courses at the Recanati Graduate School of Business Administration, Tel Aviv University and in Tel- Aviv College. Domnitz Gishri holds a B.A. in Accounting, an LL.B and a MBA (majoring in financial management), all from Tel- Aviv University, Israel.

Commenting on her appointment, Limor Domnitz Gishri, CEO of Allium, said: "When I first arrived at Allium Medical it was primarily an R&D company. I'm proud to say that now in the short span of two years Allium has become a sales and distribution company- making steady revenues. I'm excited to further move this company forward by offering the global healthcare community innovative solutions by consolidating our marketing and business activity in Europe and other vibrant markets all around the world."


Allium Medical Founder, President and CSO, Prof. Daniel Yachia, added: "Limor's expertise will provide a key source of strategic input and it will be instrumental in all factors of our commercialization, through research, manufacturing, and distribution.  In addition, she adds a dynamic element to our management group and we are thrilled that she accepted this challenge of leading Allium to realize its market potential. "





About Allium Medical

Allium Medical, Inc., is a medical device company offering next-generation stents based on a revolutionary technological platform that enables physicians to offer more effective stent solutions for enhancing patients' quality of life. Allium Medical has developed site-specific, anatomically compatible stents with applications in the urinary and gastro-intestinal tracts. Founded in 2001, Allium Medical is a privately owned company led by Professor Daniel Yachia M.D., an urologist and acknowledged international authority on urinary system stenting. Allium was awarded two CE marks for its biliary and ureteral stents, commenced sales in Europe in June 2007 and received follow-on orders from its distributors. Allium's headquarters, manufacturing and R&D facilities are located in Caesarea, Israel. For more information:


Press Contact:

Shlomit Weisblum PR Consultant

Koteret International

Tel. +972 3 575 5778 #4

Mobile +972 54 2152654

Fax +972 3 575 5887

[email protected]